Clinical trial · no report yet · Phase 3
MARIPOSA-2
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- NCT04988295 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 381 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 164 | |
| Podcasts | 110 | |
| YouTube | 105 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib; Amivantamab; Pemetrexed; Carboplatin
- Arms
- Arm A: LACP/ACP-L · Experimental
- Arm B: CP (Carboplatin and Pemetrexed) · Active comparator
- Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed) · Experimental
- Arm A2 (Extension Cohort): ACP-L · Experimental
- Arm C2 (Extension Cohort): ACP · Experimental
- Enrollment
- 776
- Primary outcomes
- Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
- Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review
- Sponsor
- Janssen Research & Development, LLC
- Start
- Nov 17, 2021
- Primary completion
- Jul 10, 2023
- Results posted
- Yes
- Registry record
- NCT04988295 · updated Sep 28, 2026